A5003909570- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Cytomegalovirus and herpesvirus research
- Telomeres, Telomerase, and Senescence
- AI in cancer detection
- Hepatitis Viruses Studies and Epidemiology
- Chronic Obstructive Pulmonary Disease (COPD) Research
- MRI in cancer diagnosis
- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- HIV/AIDS drug development and treatment
- Ferroptosis and cancer prognosis
- Advanced X-ray and CT Imaging
- Cancer, Lipids, and Metabolism
Chang Gung Memorial Hospital
2019-2025
Linkou Chang Gung Memorial Hospital
2021-2025
Washington University in St. Louis
2024-2025
Chang Gung University
2019-2024
China Medical University
2013
China Medical University Hospital
2013
Background and Aims: Long-term nucleos(t)ide analog (Nuc) treatment can reduce HCC in patients with HBV-related liver cirrhosis (HBV-LC). Earlier small cohort studies showed a comparable 5-year incidence of HBeAg-negative HBV-LC who stopped those continued Nuc therapy. This study aimed to validate these findings using large 10-year follow-up. Approach Results: From 2 centers, 494 (finite group) 593 (continuous therapy were recruited. HCC, HBsAg loss, liver-related mortality/transplantation,...
Abstract Background & Aims Clinical relapse occurs much earlier and more frequently in hepatitis B e antigen (HBeAg)‐negative chronic (CHB) patients after stopping tenofovir (TDF) therapy than those off‐entecavir (ETV). may subside or progress to flare which poses a safety concern. This study compared the incidence, timing severity of flares TDF ETV. Methods HBeAg‐negative CHB who had stopped ETV were included study. Off‐therapy patterns between off‐ETV off‐TDF before propensity score...
Colorectal cancer (CRC) metastasis is highly aggressive and associated with poor outcomes. Recent studies have highlighted greater heterogeneity in gene expression within metastatic tumor cells compared to primary cells. However, the underlying factors driving these differences remain poorly understood. We hypothesize that both genetic alterations microenvironment play key roles shaping this heterogeneity. To investigate aspects, we established a cohort through Human Tumor Atlas Network...
Abstract Introduction: Landmark cancer genome sequencing programs have significantly advanced research, leading to novel therapies and preventive strategies. However, the underrepresentation of racial minority groups in these studies limits applicability findings leaves critical gaps understanding disparities. The Participant Engagement Cancer Genome Sequencing (PE-CGS) Network, established under National Institute’s Moonshot, seeks address by engaging with understudied populations. Multiple...
CD4+ regulatory T cells (Tregs) play a critical role in the progression of hepatocellular carcinoma (HCC). However, indiscriminate depletion Tregs risks triggering autoimmunity. While previous research highlights phenotypic and functional heterogeneity Treg subpopulations, unified classification system remains elusive. This study aims to characterize subtypes HCC patients using single-cell CITE-seq validate their clinical relevance prognostic potential. profiling 51,067 from eight identified...
Abstract Liver senescence involves the gradual deterioration of hepatic cell function and reduction regenerative capacity due to aging, chronic liver disease, cancer. To elucidate role in aging cancer, we employed single-cell sequencing, spatial omics, imaging approaches, collectively over 100 assays, characterize 43 normal samples from a cohort 95 donors, across ages selected based on histology clinical data. We conducted similar assays 24 patients with colorectal cancer metastasis liver....
Summary Background Quantitative hepatitis B surface antigen (qHBsAg) level at end‐of‐treatment (EOT) predict clinical relapse (CR) after nucleos(t)ide analogues (Nuc) in chronic B(CHB) patients. It is unclear if higher EOT qHBsAg leads to earlier onset or more severe off‐Nuc CR. Aim This large cohort study investigates the association between and CR onset/severity. Methods enrolled HBeAg‐negative CHB patients who had achieved undetectable HBV DNA for over 1 year receiving Nuc therapy before...
Abstract Background Off-therapy hepatitis flare may be detrimental or, conversely, facilitate B surface antigen (HBsAg) decline. Retreatment decisions are crucial. Methods HBsAg was quantified before and during flares, at peak/retreatment start Months 6 12 in 336 entecavir/tenofovir-retreated 105 non-retreated e (HBeAg)-negative patients. Increasing ALT defined a ‘virus-dominating flare’ decreasing ‘host-dominating flare’. Results Two hundred eighty-eight retreated patients with...
Hepatocellular carcinoma (HCC) can be potentially discovered from abdominal computed tomography (CT) studies under varied clinical scenarios (e.g., fully dynamic contrast-enhanced [DCE] studies, noncontrast [NC] plus venous phase [VP] or NC-only studies). Each scenario presents its own challenges that could benefit computer-aided detection (CADe) tools. We investigate whether a single CADe model made flexible enough to handle different contrast protocols and this flexibility imparts...
In HBeAg negative chronic hepatitis B (CHB) patients, clinical relapse (CR) occurs more frequently, much earlier and often severely after stopping tenofovir (TDF) other nucleos(t)ide analogues (Nucs) than entecavir (ETV). It is unknown whether off-Nuc flare can be alleviated by switching from one Nuc to another.HBeAg-negative CHB patients who had stopped according the APASL rule been followed-up for > 48 weeks cessation were recruited. Patients classified as four groups: ETV monotherapy...
HBeAg loss during nucleos(t)ide analogue (Nuc) therapy is significantly higher in patients with hepatitis flare (ALT ≥ 5-times upper limited of normal). It not clear whether ALT level above the leads to greater rate nor its durability. This study aimed investigate impact pretherapy on each year Nuc treatment. Entecavir or Tenofovir treated HBeAg-positive chronic B (CHB) were recruited consecutively. Patients prior treatment history that experienced seroconversion and reversion excluded....
Abstract Liver senescence, marked by the progressive decline in hepatic cell function and regenerative capacity, plays a vital role context of aging, chronic liver diseases, cancer progression, particularly when influenced anti-cancer therapies. This study is designed to extensively characterize senescence under two specific conditions: replicative aging therapy-induced changes. We examined samples from 20 individuals, covering wide age range (young, <40 years; old, >60 years),...
The bronchiectasis severity index (BSI) and FACED score are currently used in predicting outcomes of non-cystic fibrosis (NCFB). Distance-saturation product (DSP), the distance walked, lowest oxygen saturation during 6-min walk test showed strong predictive power mortality non-CF patients. This study aimed to compare efficacy these scores DSP mortality.
Abstract Transarterial chemoembolization (TACE) is the standard of care for intermediate‐stage hepatocellular carcinoma (HCC) patients. The postembolization fever (PEF) observed in 20% to 73% This study aims investigate predictive factors PEF and its impact on therapeutic response. From 2010 2015, a total 525 HCC treatment naïve patients treated by TACE were recruited. Age, gender, etiologies HCC, cirrhosis, tumor status, pretherapy liver biochemistry compared between with without PEF....